fibronectin type III and SPRY domain containing 1 likeGenealiases: CCDC10 · CSDUFD1 · FSD1CL · FSD1NL · MIR1
Q-omics provides the consensus-scored FSD1L profile across patient tissues and cancer cell-line models. FSD1L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FSD1L is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, FSD1L protein abundance shows 21,206 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, and GBM as cancer lineages where FSD1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSD1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSD1L survival associations across molecular data types. FSD1L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSD1L RNA expression–survival associations across cancer types. High FSD1L expression shows unfavorable associations in LIHC, BLCA, CESC and ACC, but favorable associations in THYM and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FSD1L RNA expression.
This table summarizes FSD1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FSD1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSD1L shows lower tumor expression in KIRC and LUSC and higher tumor expression in LIHC, BRCA, COAD and CHOL. The LIHC box plot shows higher FSD1L RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with FSD1L in patient tissues and cancer cell lines. In patient samples, FSD1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FSD1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
